Pharvaris N.V. (NASDAQ:PHVS – Get Free Report) Director Elisabeth Bjork sold 10,000 shares of the company’s stock in a transaction that occurred on Wednesday, May 20th. The shares were sold at an average price of $29.32, for a total value of $293,200.00. Following the completion of the transaction, the director directly owned 15,167 shares in the company, valued at approximately $444,696.44. The trade was a 39.73% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.
Pharvaris Stock Down 2.3%
Shares of PHVS traded down $0.69 during trading on Friday, reaching $29.85. The company’s stock had a trading volume of 171,274 shares, compared to its average volume of 226,219. The company has a fifty day moving average of $28.41 and a two-hundred day moving average of $26.79. Pharvaris N.V. has a twelve month low of $15.46 and a twelve month high of $33.33. The company has a market cap of $1.95 billion, a price-to-earnings ratio of -9.43 and a beta of -2.34.
Pharvaris (NASDAQ:PHVS – Get Free Report) last announced its earnings results on Tuesday, May 12th. The company reported ($0.70) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.82) by $0.12. As a group, equities analysts forecast that Pharvaris N.V. will post -3.25 EPS for the current fiscal year.
Hedge Funds Weigh In On Pharvaris
Wall Street Analysts Forecast Growth
A number of equities analysts have issued reports on the company. Royal Bank Of Canada cut their target price on Pharvaris from $52.00 to $51.00 and set an “outperform” rating on the stock in a research report on Monday, April 6th. Citigroup reiterated a “buy” rating on shares of Pharvaris in a report on Wednesday, April 15th. Wall Street Zen upgraded Pharvaris from a “strong sell” rating to a “sell” rating in a report on Saturday, May 16th. UBS Group set a $74.00 price target on Pharvaris in a report on Wednesday, May 13th. Finally, Wedbush boosted their price target on Pharvaris from $41.00 to $42.00 and gave the company an “outperform” rating in a report on Tuesday, April 7th. Ten research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $49.18.
Check Out Our Latest Research Report on PHVS
Pharvaris Company Profile
Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.
The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.
Read More
- Five stocks we like better than Pharvaris
- SpaceX IPO: Opportunity? Or the Ultimate Hype Trade?
- CAVA Group’s Stock Looks Delicious After Strong Earnings
- Lowe’s Finds Support at $215 After Q1 Earnings Sell-Off
- Deere Beats Q2 Estimates, But Ag Weakness Weighs on Outlook
Receive News & Ratings for Pharvaris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharvaris and related companies with MarketBeat.com's FREE daily email newsletter.
